Index RUT
P/E -
EPS (ttm) -1.81
Insider Own 3.76%
Shs Outstand 89.90M
Perf Week -22.84%
Market Cap 1.60B
Forward P/E 65.45
EPS next Y 0.27
Insider Trans -9.27%
Shs Float 87.40M
Perf Month -32.32%
Income -155.20M
PEG -
EPS next Q 0.02
Inst Own 102.25%
Short Float 5.14%
Perf Quarter -36.50%
Sales 802.20M
P/S 1.99
EPS this Y 135.73%
Inst Trans -1.62%
Short Ratio 6.30
Perf Half Y -26.64%
Book/sh 8.15
P/B 2.16
EPS next Y 178.24%
ROA -13.66%
Short Interest 4.49M
Perf Year 7.53%
Cash/sh 1.07
P/C 16.40
EPS next 5Y 57.00%
ROE -21.03%
52W Range 15.99 - 29.30
Perf YTD -8.20%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -17.83%
52W High -40.03%
Beta 1.97
Dividend TTM -
Quick Ratio 1.78
Sales past 5Y 4.63%
Gross Margin 63.71%
52W Low 9.85%
ATR (14) 1.18
Dividend Ex-Date -
Current Ratio 1.96
EPS Y/Y TTM 40.77%
Oper. Margin -13.86%
RSI (14) 21.33
Volatility 8.12% 5.30%
Employees 2700
Debt/Eq 0.19
Sales Y/Y TTM 14.78%
Profit Margin -19.35%
Recom 2.62
Target Price 29.60
Option/Short Yes / Yes
LT Debt/Eq 0.18
EPS Q/Q 71.49%
Payout -
Rel Volume 2.02
Prev Close 17.61
Sales Surprise 2.45%
EPS Surprise 527.35%
Sales Q/Q 15.26%
Earnings Nov 07 AMC
Avg Volume 713.42K
Price 17.57
SMA20 -19.71%
SMA50 -29.61%
SMA200 -26.12%
Trades
Volume 1,438,093
Change -0.23%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-19-24 Initiated
Morgan Stanley
Equal-Weight
$32
Aug-28-24 Initiated
Wells Fargo
Overweight
$35
Jun-27-24 Initiated
Scotiabank
Sector Outperform
$29
Jun-03-24 Resumed
Jefferies
Underperform
$20
May-08-24 Upgrade
Leerink Partners
Market Perform → Outperform
$25 → $35
Dec-21-23 Resumed
Piper Sandler
Neutral
$23
Dec-19-23 Initiated
Wells Fargo
Equal Weight
$20
Dec-14-23 Initiated
Guggenheim
Buy
$23
Dec-13-23 Initiated
Wolfe Research
Outperform
$28
Jul-05-23 Resumed
JP Morgan
Underweight
$18
May-23-23 Upgrade
Goldman
Sell → Buy
$18 → $25
Jan-18-23 Upgrade
Raymond James
Mkt Perform → Outperform
$25
Oct-06-22 Initiated
Stephens
Equal-Weight
$22
Oct-15-21 Resumed
Cowen
Market Perform
$33
Jun-15-21 Initiated
Raymond James
Mkt Perform
Jun-03-21 Initiated
Goldman
Sell
$25
Sep-26-19 Downgrade
BofA/Merrill
Neutral → Underperform
$30 → $28
Aug-14-19 Downgrade
Piper Jaffray
Overweight → Neutral
$45 → $40
Aug-02-19 Upgrade
BofA/Merrill
Underperform → Neutral
Aug-01-19 Upgrade
Barclays
Underweight → Equal Weight
$18 → $40
Show Previous Ratings
Nov-04-24 08:39AM
Nov-02-24 11:15AM
Nov-01-24 06:55PM
(Morningstar Research) -18.08%
Oct-30-24 08:00AM
Oct-28-24 10:01AM
02:19PM
Loading…
Oct-22-24 02:19PM
Oct-16-24 09:00AM
Oct-15-24 09:00AM
Oct-09-24 07:49AM
(Clinical Trials Arena) -6.12%
Oct-08-24 04:05PM
Oct-04-24 06:33AM
Oct-03-24 09:00AM
Oct-01-24 04:05PM
Sep-25-24 06:38PM
Sep-18-24 09:50AM
08:00AM
Loading…
08:00AM
Sep-16-24 06:37PM
Sep-13-24 01:54AM
01:54AM
Sep-10-24 01:17AM
Sep-05-24 11:31AM
08:00AM
01:33AM
Sep-04-24 06:50PM
(Morningstar Research) -7.65%
Aug-30-24 09:50AM
Aug-23-24 07:01PM
Aug-21-24 08:00AM
Aug-20-24 07:01PM
Aug-09-24 07:07PM
Aug-08-24 08:16AM
10:36PM
Loading…
Aug-07-24 10:36PM
Aug-06-24 07:00PM
06:30PM
05:28PM
(Associated Press Finance)
04:05PM
Aug-01-24 04:05PM
Jul-31-24 08:50AM
Jul-30-24 08:00AM
Jul-17-24 08:00AM
Jul-15-24 02:01PM
Jul-11-24 09:00AM
Jul-10-24 07:53AM
Jul-09-24 09:00AM
Jul-08-24 09:00AM
Jul-03-24 07:07PM
Jul-02-24 09:00AM
Jun-24-24 04:05PM
Jun-12-24 11:46AM
Jun-11-24 09:36AM
08:00AM
Jun-06-24 11:31AM
Jun-05-24 02:35AM
Jun-04-24 09:00AM
Jun-03-24 04:05PM
May-30-24 05:55PM
May-23-24 06:44PM
06:00PM
May-16-24 04:05PM
02:52AM
02:52AM
May-13-24 09:45AM
May-10-24 06:00AM
May-09-24 06:55PM
(Morningstar Research) +5.43%
May-08-24 04:28PM
03:59PM
01:54PM
01:24PM
12:15PM
03:47AM
May-07-24 09:56PM
07:00PM
06:02PM
05:50PM
04:47PM
(Associated Press Finance)
04:05PM
09:00AM
Apr-30-24 04:05PM
Apr-24-24 10:01AM
Apr-17-24 08:00AM
Apr-16-24 09:15AM
Apr-11-24 10:00AM
Apr-09-24 09:10AM
08:00AM
Mar-28-24 11:30AM
Mar-27-24 07:51AM
Mar-21-24 09:40PM
Mar-20-24 04:05PM
Mar-01-24 09:41AM
Feb-28-24 02:45PM
(Morningstar Research) -8.04%
11:24AM
(Thomson Reuters StreetEvents)
10:24AM
07:50AM
Feb-27-24 07:00PM
06:30PM
04:42PM
04:05PM
09:15AM
Feb-26-24 09:16AM
Feb-21-24 04:05PM
Feb-16-24 07:05AM
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DIAZ PAUL J President and CEO Oct 11 '24 Sale 22.93 15,000 343,950 962,378 Oct 11 05:23 PM DIAZ PAUL J Officer Oct 11 '24 Proposed Sale 22.93 15,000 343,950 Oct 11 10:35 AM Ancona Margaret Officer Aug 21 '24 Proposed Sale 27.82 11,538 321,019 Sep 16 02:30 PM DIAZ PAUL J President and CEO Sep 11 '24 Sale 26.72 15,000 400,800 977,378 Sep 12 04:11 PM Muzzey Dale Chief Scientific Officer Sep 11 '24 Sale 26.17 2,100 54,961 108,013 Sep 12 04:09 PM Muzzey Dale Officer Sep 11 '24 Proposed Sale 26.17 2,100 54,961 Sep 11 03:26 PM DIAZ PAUL J Officer Sep 11 '24 Proposed Sale 26.72 15,000 400,800 Sep 11 10:05 AM Dreismann Heinrich Director Sep 09 '24 Sale 27.05 10,000 270,520 121,648 Sep 09 05:48 PM Dreismann Heinrich Director Sep 10 '24 Proposed Sale 27.00 10,000 270,000 Sep 09 02:52 PM Reitan Colleen F Director Sep 03 '24 Sale 27.95 46,012 1,285,851 42,533 Sep 04 07:38 PM Reitan Colleen F Director Sep 03 '24 Proposed Sale 28.19 46,012 1,297,078 Sep 03 10:11 AM Ancona Margaret SVP, Chief of Staff Aug 21 '24 Sale 27.82 11,538 320,987 79,366 Aug 23 04:16 PM Kumar Rashmi Director Aug 19 '24 Sale 28.01 7,500 210,075 77,392 Aug 20 04:38 PM Kumar Rashmi Director Aug 19 '24 Proposed Sale 28.01 7,500 210,075 Aug 19 02:46 PM SPIEGELMAN DANIEL K Director Jun 04 '24 Sale 22.05 3,788 83,525 32,917 Jun 04 05:57 PM SPIEGELMAN DANIEL K Director Jun 03 '24 Sale 22.04 3,788 83,488 36,705 Jun 04 05:57 PM DIAZ PAUL J President and CEO May 14 '24 Sale 25.21 95,000 2,394,798 1,141,166 May 15 05:49 PM DIAZ PAUL J President and CEO May 15 '24 Sale 25.07 75,000 1,880,415 1,066,166 May 15 05:49 PM DIAZ PAUL J President and CEO May 13 '24 Sale 25.13 57,844 1,453,550 1,236,166 May 15 05:49 PM Newcomer Lee Nisley Director May 13 '24 Sale 25.30 6,200 156,860 66,650 May 15 05:48 PM Riggsbee Richard Bryan Chief Financial Officer Dec 01 '23 Sale 19.09 30,000 572,835 291,812 Dec 05 04:19 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite